FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:578-580 August 24, 2000 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Roy, D. PubMed Citation

To the Editor: Roy et al. (March 30 issue)¹ report that amiodarone is more efficacious than sotalol or propafenone for the prevention of recurrences of atrial fibrillation. However, a significantly greater proportion of the patients assigned to sotalol or propafenone had left ventricular hypertrophy (21 percent) than of those assigned to amiodarone (13 percent) (P=0.04). As we already know, hypertensive heart disease is the most common antecedent to the development of atrial fibrillation.²

Some of the greater efficacy of amiodarone, as compared with the other two agents, can be explained by the difference between the two groups in the prevalence . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.